Ambry

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Ambry Genetics will use Agilent Technologies' SureSelect Target Enrichment System for the exome sequencing services it provides for its customers, the firms announced today.

Products

Premium

RainDance Technologies and Ambry Genetics have launched ADMESeq, a targeted sequencing panel that will sequence 242 genes involved with drug absorption, distribution, metabolism, and excretion.

By Julia Karow
This article has been updated from a previous version to attribute Ambry's comments to the company's assistant medical director.

Ambry Genetics will be the first authorized service provider for a new high-throughput target enrichment system being developed by RainDance Technologies, the companies announced last week.

By Justin Petrone
Growing demand for arrays designed to detect tumor copy-number changes is enticing more chip manufacturers to offer tools tailor-made for cancer research.

New Product Watch

Premium

Ambry Genetics last week launched its CancerArray, an exon-focused, 180,000-probe array for comparative genomic hybridization.

Ambry's StemArray is manufactured by Roche NimbleGen and enables researchers studying stem cells to detect genomic abnormalities that would ordinarily be missed by low-resolution karyotyping.

Pages

The data generated by 100,000 Genomes Project is being housed on military servers due to attacks by hackers, Naked Security reports.

A new poll finds most US adults are not familiar with personalized medicine, according to HealthDay.

Vox reports that the United Nations' Convention on Biological Diversity decided against a gene drive moratorium.

In Science this week: sequencing of neuroblastomas uncovers alterations linked to prognosis, and more.